Summit Therapeutics Inc. Cash Equivalents, at Carrying Value
Summit Therapeutics Inc. (SMMT) had Cash Equivalents, at Carrying Value of $60.07 million as of 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Cash and Cash Equivalent
us-gaap:CashEquivalentsAtCarryingValue · last filed 2023-03-09
- 2022-09-30: Cash Equivalents, at Carrying Value $60.07M.
- 2021-12-31: Cash Equivalents, at Carrying Value $0.00.
| Period end | Cash Equivalents, at Carrying Value |
|---|---|
| 2022-09-30 | $60.07M 10-Q · filed 2022-11-09 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |